Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2025)

Historic Receivables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $32000.0.

  • Corvus Pharmaceuticals' Receivables fell 7714.29% to $32000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $32000.0, marking a year-over-year decrease of 7714.29%. This contributed to the annual value of $75000.0 for FY2024, which is 4423.08% up from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Receivables stood at $32000.0 for Q3 2025, which was down 7714.29% from $86000.0 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Receivables' 5-year high stood at $1.2 million during Q4 2022, with a 5-year trough of $11000.0 in Q3 2023.
  • For the 4-year period, Corvus Pharmaceuticals' Receivables averaged around $177300.0, with its median value being $72500.0 (2024).
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Receivables tumbled by 9557.82% in 2023, and later skyrocketed by 117272.73% in 2024.
  • Corvus Pharmaceuticals' Receivables (Quarter) stood at $1.2 million in 2022, then plummeted by 95.58% to $52000.0 in 2023, then skyrocketed by 44.23% to $75000.0 in 2024, then tumbled by 57.33% to $32000.0 in 2025.
  • Its last three reported values are $32000.0 in Q3 2025, $86000.0 for Q2 2025, and $79000.0 during Q1 2025.